Skip to main content
. 2021 Apr 13;54(5):1083–1095.e7. doi: 10.1016/j.immuni.2021.04.003

Figure 1.

Figure 1

Clinical features of moderate and severe MIS-C

(A) Yale New Haven Hospital (YNHH) timeline of total daily adult COVID-19 hospitalizations (blue) and MIS-C cumulative cases (red).

(B) Clinical time course of moderate and severe patients showing symptom onset and treatments relative to hospital admission (Day 0).

(C) PCA biplot for clinical parameters, where available for MIS-C patients. P13, P7, and P21 were excluded due to unavailable measurements for troponin, BNP, and ALC, respectively.

(D) Clinical laboratory data for the indicated analyte. Normal range represented by gray shading. BNP, B-type natriuretic peptide; CRP, C-reactive protein; ALC, absolute lymphocyte count; AST, aspartate aminotransferase; ALT, alanine aminotransferase; WBC, white blood cells; CKD, chronic kidney disease; CHF, chronic heart failure.